An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity

Critical Reviews in Toxicology

Volumn 41, Issue 10, 2011, Pages 803-821

  Snchez Gonzlez, Penélope D ^a,b   López Hernández, Francisco J ^b,c   López Novoa, José M ^b   Morales, Ana I ^a,b  

^a Unidad de Toxicología   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c Instituto de Estudios de Ciencias de La Salud de Castilla y Leon   (Spain)

Author keywords

Cisplatin; glomerular injury; nephrotoxicity; tubular dysfunction; vascular abnormalities

Indexed keywords

CATALASE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; FUROSEMIDE; GEMCITABINE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; METHOTREXATE; MITOMYCIN; NAVELBINE; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PACLITAXEL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; SUPEROXIDE DISMUTASE; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; AEROBIC METABOLISM; ANUS CANCER; APOPTOSIS; BLADDER CARCINOMA; BLOOD VESSEL INJURY; BREAST CANCER; CALCIUM TRANSPORT; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL TRANSPORT; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DNA DAMAGE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVATION; ENZYMURIA; ESOPHAGUS CANCER; GLOMERULITIS; GLOMERULUS FILTRATION RATE; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; IMMUNE RESPONSE; INFLAMMATION; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE CELL; KIDNEY TUBULE DAMAGE; KIDNEY TUBULE NECROSIS; KIDNEY VASCULAR RESISTANCE; LIPID PEROXIDATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDULLOBLASTOMA; MESOTHELIOMA; MITOCHONDRION; MOLECULAR WEIGHT; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NITROSATIVE STRESS; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; OXIDATIVE STRESS; PANCREAS CANCER; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYURIA; PRIMARY TUMOR; PROTEIN PHOSPHORYLATION; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REVIEW; RISK FACTOR; SALT WASTING; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TRANSITIONAL CELL CARCINOMA; UREA BLOOD LEVEL; URINE OSMOLALITY; URINE VOLUME; UTERINE CERVIX CANCER; VASCULARIZATION; VASOCONSTRICTION;

ACUTE DISEASE; ANIMALS; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; CISPLATIN; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DNA DAMAGE; HUMANS; KIDNEY; KIDNEY GLOMERULUS; KIDNEY TUBULAR NECROSIS, ACUTE; KIDNEY TUBULES; RISK FACTORS;

EID: 81255195586     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2011.602662     Document Type: Review

References (192)

1. Aggarwal BB, Takada Y, Shishodia S, Gutierrez AM, Oommen OV, Ichikawa H, Baba Y, Kumar A. (2004). Nuclear transcription factor NF-kappa B: role in biology and medicine. Indian J Exp Biol 42:341-353. (Pubitemid 38449055)
2. Ahn JH, Kang YK, Kim TW, Bahng H, Chang HM, Kang WC, Kim WK, Lee JS, Park JS. (2002). Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Cancer Chemother Pharmacol 50:104-110. (Pubitemid 34969504)
3. Ali BH, Al-Moundhri M, Tageldin M, Al Husseini IS, Mansour MA, Nemmar A, Tanira MO. (2008). Ontogenic aspects of cisplatin-induced nephrotoxicity in rats. Food Chem Toxicol 46:3355-3359.
4. Antunes LM, Darin JD, Bianchi Nde L. (2001). Efects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol Res 43:145-150. (Pubitemid 32601443)
5. Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P. (2003). Biweekly low-dose sequential gemcitabine, 5-fuorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. Cancer Invest 21:489-496. (Pubitemid 37169551)
6. Arany I, Safrstein RL. (2003). Cisplatin nephrotoxicity. Semin Nephrol 23:460-464. (Pubitemid 37176691)
7. Arany I, Megyesi JK, Kaneto H, Price PM, Safrstein RL. (2004). Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol 287:F543-F549. (Pubitemid 39095970)
8. Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA. (2004). Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 22:262-268. (Pubitemid 41095090)
9. Aydinoz S, Uzun G, Cermik H, Atasoyu EM, Yildiz S, Karagoz B, Evrenkaya R. (2007). Efects of diferent doses of hyperbaric oxygen on cisplatin-induced nephrotoxicity. Ren Fail 29: 257-263. (Pubitemid 46752362)
10. Azzoli CG, Krug LM, Miller VA, Rizvi NA, Kris MG, Dunne M, Farmer A, Pizzo B, Tyson L, Seeger T, Coleman B, Moore E, Lastinger L, Venkatraman E, Rudin CM. (2007). A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer. J Torac Oncol 2:638-644. (Pubitemid 47171786)
11. Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, Briccoli A, Forni C; Italian Sarcoma Group/Scandinavian Sarcoma Group. (2002). High dose ifosfamide in combination with high dose methotrexate, adri-amycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother 14:198-206. (Pubitemid 34460560)
12. Badary OA, Abdel-Maksoud S, Ahmed WA, Owieda GH. (2005). Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci 76:2125-2135. (Pubitemid 40249370)
13. Bae EH, Lee J, Ma SK, Kim IJ, Frøkiaer J, Nielsen S, Kim SY, Kim SW. (2009). alpha-Lipoic acid prevents cisplatin-induced acute kidney injury in rats. Nephrol Dial Transplant 24:2692-2700.
14. Barabas K, Milner R, Lurie D, Adin C. (2008). Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol 6:1-18.
15. Bearcroft CP, Domizio P, Mourad FH, André EA, Farthing MJ. (1999). Cisplatin impairs fuid and electrolyte absorption in rat small intestine: a role for 5-hydroxytryptamine. Gut 44:174-179. (Pubitemid 29119359)
16. Bhide SA, Ahmed M, Barbachano Y, Newbold K, Harrington KJ, Nutting CM. (2008). Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer. Br J Cancer 99:57-62.
17. Boulikas T. (2009. Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 18:1197-1218.
18. Boyce M, Yuan J. (2006). Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Difer 13:363-373.
19. Brodsky SV, Yamamoto T, Tada T, Kim B, Chen J, Kajiya F, Goligorsky MS. (2002). Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. Am J Physiol Renal Physiol 282:F1140-F1149. (Pubitemid 34654480)
20. Brooks C, Wei Q, Cho SG, Dong Z. (2009). Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 119:1275-1285.
21. Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, Wiemer EA. (2010). Diferential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol 159:898-908.
22. Cetin R, Devrim E, Kiliçoglu B, Avci A, Candir O, Durak I. (2006). Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. J Appl Toxicol 26:42-46. (Pubitemid 43171334)
23. Chang B, Nishikawa M, Sato E, Utsumi K, Inoue M. (2002). L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys 405:55-64. (Pubitemid 35026166)
24. Chiara S, Lionetto R, Vincenti M, Bruzzone M, Nobile MT, Gadducci A, Carnino F, Rosso R, Conte P F. (2001. Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. Crit Rev Oncol Hematol 37:27-34. (Pubitemid 32065665)
25. Chirino YI, Pedraza-Chaverri J. (2009). Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 61:223-242.
26. Chirino YI, Trujillo J, Sánchez-González DJ, Martínez-Martínez CM, Cruz C, Bobadilla NA, Pedraza-Chaverri J. (2008). Selective iNOS inhibition reduces renal damage induced by cisplatin. Toxicol Lett 176:48-57. (Pubitemid 50008205)
27. Choi DE, Jeong JY, Lim BJ, Lee KW, Shin YT, Na KR. (2009). Pretreatment with darbepoetin attenuates renal injury in a rat model of cisplatin-induced nephrotoxicity. Korean J Intern Med 24: 238-246.
28. Choudhury D, Ahmed Z. (2006). Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2:80-91. (Pubitemid 43355216)
29. Chumworathayi B, Yuenyao P, Tangvorapongchai V, Luanratanakorn S, Pattamadilok J, Krusun S. (2007). Weekly gemcitabine and cisplatin concurrent with pelvic irradiation for primary therapy of cervical cancer: report of the frst seven cases in Tai women. Radiat Med 25:474-479. (Pubitemid 351928014)
30. Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstädt H, Lanvers-Kaminsky C, am Zehnhof-Dinnesen A, Schinkel AH, Koepsell H, Jürgens H, Schlatter E. (2010). Organic cation transporter 2 mediates cisplatin-induced oto-and nephrotoxicity and is a target for protective interventions. Am J Pathol 176:1169-1180.
31. Cohen SM, Lippard SJ. (2001). Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67:93-130. (Pubitemid 33804642)
32. Cornelison TL, Reed E. (1993). Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 50:147-158. (Pubitemid 23275196)
33. Cubillo A, Cornide M, López JL, Molina R, Feliu J, Espinosa E, Zamora P, de Castro J, Ordoñez A, González Barón M. 2001. Renal tolerance to cisplatin in patients 70 years and older. Am J Clin Oncol 24:192-197. (Pubitemid 32323359)
34. Cummings BS, McHowat J, Schnellmann RG. (2004). Role of an endoplasmic reticulum Ca2+independent phospholipase A2 in cisplatin-induced renal cell apoptosis. J Pharmacol Exp Ter 308:921-928. (Pubitemid 38263966)
35. Cummings BS, Schnellmann RG. (2002). Cisplatin-induced renal cell apoptosis: caspase 3-dependent and-independent pathways. J Pharmacol Exp Ter 302:8-17. (Pubitemid 34680415)
36. Daugaard G, Abildgaard U. (1989). Cisplatin nephrotoxicity. A review. Cancer Chemother Pharmacol 25:1-9.
37. De Jongh R, Groenink L, van der Gugten J, Olivier B. (2003). Light-enhanced and fear-potentiated startle: temporal characteristics and efects of alpha-helical corticotropin-releasing hormone. Biol Psychiatry 54:1041-1048. (Pubitemid 37415039)
38. Delbancut A, Lagroye I, Cambar J. (1994). Renal cytotoxicity of cisplatin in cultured glomerular mesangial and proximal and distal tubular cells. Toxicol In Vitro 8:517-519. (Pubitemid 24312715)
39. Dhillon AS, Hagan S, Rath O, Kolch W. (2007). MAP kinase signalling pathways in cancer. Oncogene 26:3279-3290. (Pubitemid 46763021)
40. Dogliotti L, Cartenì G, Siena S, Bertetto O, Martoni A, Bono A, Amadori D, Onat H, Marini L. (2007). Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as frst-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52:134-141. (Pubitemid 46803003)
41. Dong G, Luo J, Kumar V, Dong Z. (2010). Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells. Am J Physiol Renal Physiol 298:F293-F300.
42. dos Santos O F, Boim MA, Barros EJ, Pirotzky E, Braquet P, Schor N. (1991). Efect of platelet-activating factor antagonist BN 52063 on the nephrotoxicity of cisplatin. Lipids 26:1324-1328.
43. Dutta J, Fan Y, Gupta N, Fan G, Gélinas C. (2006). Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 25:6800-6816. (Pubitemid 44657853)
44. Eardley KS, Kubal C, Zehnder D, Quinkler M, Lepenies J, Savage CO, Howie AJ, Kaur K, Cooper MS, Adu D, Cockwell P. (2008). Te role of capillary density, macrophage infltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 74:495-504.
45. Ekborn A, Lindberg A, Laurell G, Wallin I, Eksborg S, Ehrsson H. (2003). Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig. Cancer Chemother Pharmacol 51:36-42. (Pubitemid 36057021)
46. Faivre C, Rougier P, Ducreux M, Mitry E, Lusinchi A, Lasser P, Elias D, Eschwege F. (1999). 5-fuorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer 86:861-865.
47. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL. (2007). Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infltration in the kidney. J Pharmacol Exp Ter 322:8-15. (Pubitemid 46956357)
48. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G; Italian and Scandinavian Sarcoma Groups. (2005). Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23:8845-8852. (Pubitemid 46211531)
49. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. (2009). Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ter 86: 396-402.
50. Francescato HD, Costa RS, Júnior FB, Coimbra TM. (2007). Efect of JNK inhibition on cisplatin-induced renal damage. Nephrol Dial Transplant 22:2138-2148. (Pubitemid 47244690)
51. Francescato HD, Costa RS, da Silva CG, Coimbra TM. (2009). Treatment with a p38 MAPK inhibitor attenuates cisplatin nephrotoxicity starting after the beginning of renal damage. Life Sci 84:590-597.
52. Fujieda, M., Matsunaga, A., Hayashi, A., Tauchi, H., Chayama, K., and Sekine, T. (2009). Children's toxicology from bench to bed-Drug-induced renal injury (2): Nephrotoxicity induced by cisplatin and ifosfamide in children. J Toxicol Sci 34 Suppl 2 SP251-257.
53. Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, De Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. (2000). Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 18:3390-3399.
54. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D. (2005). Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937-2945. (Pubitemid 46224112)
55. Gill A, Wortham K, Costa D, Davis W, Ticho B, Whalley E. (2009). Protective efect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats. Am J Nephrol 30:521-526.
56. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. (1977). Te renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39:1362-1371. (Pubitemid 8108286)
57. Goren MP. 2003. Cisplatin nephrotoxicity afects magnesium and calcium metabolism. Med Pediatr Oncol 41:186-189. (Pubitemid 36910126)
58. Grande MT, López-Novoa JM. (2009). Fibroblast activation and myofbroblast generation in obstructive nephropathy. Nat Rev Nephrol 5:319-328.
59. Greenberg HS, Chamberlain MC, Glantz MJ, Wang S. (2001). Adult medulloblastoma: multiagent chemotherapy. Neuro-oncology 3:29-34. (Pubitemid 33685583)
60. Groth S, Nielsen H, Sørensen JB, Christensen AB, Pedersen AG, Rørth M. (1986). Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol 17:191-196. (Pubitemid 16082023)
61. Guinee DG Jr, van Zee B, Houghton DC. (1993). Clinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapy. Cancer 71:4050-4054. (Pubitemid 23172990)
62. Guo Y, Liu Y, Xu LG, Guo MY. (2006). Protective efect of amifostine on cisplatin-induced nephrotoxicity and its mechanism. Zhonghua Zhong Liu Za Zhi 28:8-12.
63. Hamilton RW, Hopkins MB 3rd, Shihabi ZK. (1989). Myoglobinuria, hemoglobinuria, and acute renal failure. Clin Chem 35:1713-1720. (Pubitemid 19212440)
64. Hye Khan MA, Abdul Sattar M, Abdullah NA, Johns EJ. (2007). Cisplatin-induced nephrotoxicity causes altered renal hemodynamics in Wistar Kyoto and spontaneously hypertensive rats: role of augmented renal alpha-adrenergic responsiveness. Exp Toxicol Pathol 59:253-260. (Pubitemid 350030444)
65. Iseri S, Ercan F, Gedik N, Yüksel M, Alican I. (2007). Simvastatin attenuates cisplatin-induced kidney and liver damage in rats. Toxicology 230:256-264. (Pubitemid 46109145)
66. Isnard-Bagnis C, Moulin B, Launay-Vacher V, Izzedine H, Tostivint I, Deray G. (2005). Anticancer drug-induced nephrotoxicity. Nephrol Ter 1:101-114. (Pubitemid 41097632)
67. Jiang M, Wei Q, Pabla N, Dong G, Wang CY, Yang T, Smith SB, Dong Z. (2007). Efects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 73:1499-1510. (Pubitemid 46452592)
68. Jiang M, Wang CY, Huang S, Yang T, Dong Z. (2009). Cisplatin-induced apoptosis in p53-defcient renal cells via the intrinsic mitochondrial pathway. Am J Physiol Renal Physiol 296:F983-F993.
69. Jo SK, Cho WY, Sung SA, Kim HK, Won NH. (2005). MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing infammation and apoptosis. Kidney Int 67:458-466. (Pubitemid 40139837)
70. Jones R, Ryan M, Friedlander M. (2003). Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecol Oncol 89:112-115. (Pubitemid 36403656)
71. Jones DP, Spunt SL, Green D, Springate JE; Children's Oncology Group. (2008). Renal late efects in patients treated for cancer in childhood: a report from the Children's Oncology Group. Pediatr Blood Cancer 51:724-731.
72. Kang DG, Lee AS, Mun YJ, Woo WH, Kim YC, Sohn EJ, Moon MK, Lee HS. (2004). Butein ameliorates renal concentrating ability in cisplatin-induced acute renal failure in rats. Biol Pharm Bull 27:366-370. (Pubitemid 41685481)
73. Kang KP, Kim DH, Jung YJ, Lee AS, Lee S, Lee SY, Jang KY, Sung MJ, Park SK, Kim W. (2009). Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal infammation. Nephrol Dial Transplant 24:3012-3020.
74. Karbach U, Kricke J, Meyer-Wentrup F, Gorboulev V, Volk C, Lofng-Cueni D, Kaissling B, Bachmann S, Koepsell H. (2000). Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol 279:F679-F687.
75. Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C. (2010). Drugs renal toxicity. Nephrol Ter 6:58-74.
76. Kaushal GP, Kaushal V, Hong X, Shah S V. (2001). Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int 60:1726-1736. (Pubitemid 32999977)
77. Kawai Y, Taniuchi S, Okahara S, Nakamura M, Gemba M. (2005). Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull 28:1385-1388. (Pubitemid 41379685)
78. Kawai Y, Nakao T, Kunimura N, Kohda Y, Gemba M. (2006). Relationship of intracellular calcium and oxygen radicals to Cisplatin-related renal cell injury. J Pharmacol Sci 100:65-72. (Pubitemid 43161616)
79. Kawai Y, Satoh T, Hibi D, Ohno Y, Kohda Y, Miura K, Gemba M. (2009). Te efect of antioxidant on development of fbrosis by cisplatin in rats. J Pharmacol Sci 111:433-439.
80. Khan AH, Sattar MA, Abdullah NA, Johns EJ. (2007). Infuence of cisplatin-induced renal failure on the alpha(1)-adrenoceptor subtype causing vasoconstriction in the kidney of the rat. Eur J Pharmacol 569:110-118. (Pubitemid 47175868)
81. Khan MA, Sattar MA, Abdullah NA, Johns EJ. (2008). Alpha1B-adrenoceptors mediate adrenergically-induced renal vasoconstrictions in rats with renal impairment. Acta Pharmacol Sin 29:193-203. (Pubitemid 351178422)
82. Khan AH, Sattar MA, Abdullah NA, Johns EJ. (2009). Efect of calcium channel blockade on adrenergically induced renal vasoconstriction in rat models of renal impairment. Clin Exp Pharmacol Physiol 36:501-508.
83. Kim YK, Kim HJ, Kwon CH, Kim JH, Woo JS, Jung JS, Kim JM. (2005). Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J Appl Toxicol 25:374-382. (Pubitemid 41337233)
84. Kintzel PE. (2001). Anticancer drug-induced kidney disorders. Drug Saf 24:19-38.
85. Kishore BK, Krane CM, Di Iulio D, Menon AG, Cacini W. (2000). Expression of renal aquaporins 1, 2, and 3 in a rat model of cisplatin-induced polyuria. Kidney Int 58:701-711. (Pubitemid 30620019)
86. Klaasen CD. (2001). Casarett & Doull's Toxicology: Te Basic Science of Poisons, 6th edn. Mc Graw-Hill, New York.
87. Kohn S, Fradis M, Ben-David J, Zidan J, Robinson E. (2002). Nephrotoxicity of combined treatment with cisplatin and gentamicin in the guinea pig: glomerular injury fndings. Ultrastruct Pathol 26:371-382. (Pubitemid 36016045)
88. Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW. (2001). Irinotecan combined with gemcitabine, 5-fuorouracil, leucovorin, and cisplatin (G-FLIP) is an efective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 6:488-495. (Pubitemid 33152094)
89. Kröning R, Lichtenstein AK, Nagami GT. (2000). Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol 45: 43-49. (Pubitemid 30099714)
90. Kuhad A, Pilkhwal S, Sharma S, Tirkey N, Chopra K. (2007). Efect of curcumin on infammation and oxidative stress in cisplatin-induced experimental nephrotoxicity. J Agric Food Chem 55:10150-10155.
91. Kuhlmann MK, Burkhardt G, Köhler H. (1997). Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 12: 2478-2480. (Pubitemid 27520658)
92. Kuhnt T, Becker A, Pigorsch S, Pelz T, Bloching M, Passmann M, Lotterer E, Hänsgen G, Dunst J. (2003. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. Strahlenther Onkol 179:673-681. (Pubitemid 37254661)
93. Kuo YM, Gybina AA, Pyatskowit JW, Gitschier J, Prohaska JR. (2006). Copper transport protein (Ctr1) levels in mice are tissue specifc and dependent on copper status. J Nutr 136:21-26. (Pubitemid 43156479)
94. Kuriakose GC, Kurup MG. (2008. Evaluation of renoprotective efect of Aphanizomenon fos-aquae on cisplatin-induced renal dysfunction in rats. Ren Fail 30:717-725.
95. Lajer H, Kristensen M, Hansen HH, Christensen S, Jonassen T, Daugaard G. (2005). Magnesium and potassium homeostasis during cisplatin treatment. Cancer Chemother Pharmacol 55:231-236. (Pubitemid 40142887)
96. Lalier L, Cartron PF, Juin P, Nedelkina S, Manon S, Bechinger B, Vallette FM. (2007). Bax activation and mitochondrial insertion during apoptosis. Apoptosis 12:887-896. (Pubitemid 46653297)
97. Launay-Vacher V, Ayllon J, Janus N, Spano JP, Ray-Coquard I, Gligorov J, Pourrat X, Morere J F, Beuzeboc P, Deray G, Oudard S; Renal insufciency and anticancer medications (irma) study group. (2009). Drug management of prostate cancer: prevalence and consequences of renal insufciency. Clin Genitourin Cancer 7:E83-E89.
98. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M; European Society of Clinical Pharmacy Special Interest Group on Cancer Care. (2008a). Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61:903-909.
99. Launay-Vacher V, Isnard-Bagnis C, Janus N, Karie S, Deray G. (2008b). Chemotherapy and renal toxicity. Bull Cancer 95 FMC Onco:F96-103. (Pubitemid 351879426)
100. Lebwohl D, Canetta R. (1998). Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34:1522-1534. (Pubitemid 28446332)
101. Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, Jang YB, Lee JE, Jang KY, Park SK. (2006. Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant 21:2096-2105. (Pubitemid 44295034)
102. Li CJ, Sun JL, Jiang WJ, Liu LS, Sun XY, Fan GZ. (2009). Efect of cisplatin on expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and their correlations in Lewis lung cancer in mice. Ai Zheng 28:685-690.
103. Liedert B, Pluim D, Schellens J, Tomale J. (2006). Adduct-specifc monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res 34:e47.
104. Lin A, Jabbari S, Worden FP, Bradford CR, Chepeha DB, Teknos TN, Liao JJ, Nyquist GG, Tsien C, Schipper MJ, Urba S, Wolf GT, Eisbruch A. (2005). Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 63:1413-1418. (Pubitemid 41628036)
105. Liu H, Baliga R. (2003. Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int 63:1687-1696. (Pubitemid 36513314)
106. Lu LH, Oh DJ, Dursun B, He Z, Hoke TS, Faubel S, Edelstein CL. (2008). Increased macrophage infltration and fractalkine expression in cisplatin-induced acute renal failure in mice. J Pharmacol Exp Ter 324:111-117. (Pubitemid 350294166)
107. Luke DR, Vadiei K, Lopez-Berestein G. (1992). Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 7:1-7.
108. Martinez G, Costantino G, Clementi A, Puglia M, Clementi S, Cantarella G, De Meo L, Matera M. (2009). Cisplatin-induced kidney injury in the rat: L-carnitine modulates the relationship between MMP-9 and TIMP-3. Exp Toxicol Pathol 61:183-188.
109. Martínez-Salgado C, García-Cenador B, Fuentes-Calvo I, Macías Núñez J F, López-Novoa JM. (2007). Efect of adenosine in extracellular matrix synthesis in human and rat mesangial cells. Mol Cell Biochem 305:163-169. (Pubitemid 47517178)
110. Mené P, Simonson MS, Dunn MJ. (1989). Physiology of the mesangial cell. Physiol Rev 69:1347-1424. (Pubitemid 19255840)
111. Meyer KB, Madias NE. (1994). Cisplatin nephrotoxicity. Miner Electrolyte Metab 20:201-213. (Pubitemid 24320004)
112. Meyer-Wentrup F, Karbach U, Gorboulev V, Arndt P, Koepsell H. (1998). Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem Biophys Res Commun 248: 673-678. (Pubitemid 28404480)
113. Mihaylova Zh, Ludovini V, Gregorg V, Floriani I, Pistola L, Tofaneti F, Ferraldeschi M, Spreafco A, Ceresoli GL, Bellet M, Darwish S, Tonato M, Raynov J. (2007). Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients. J Buon 12:105-111. (Pubitemid 46824679)
114. Moscetti L, Nelli F, Padalino D, Sperduti I, Giannarelli D, Pollera CF. (2005). Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidi-ties on safety and efcacy outcome. J Chemother 17:685-692. (Pubitemid 43097759)
115. Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O, Inui K. (2002). Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13:866-874. (Pubitemid 34274082)
116. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM. (2000). Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18:106-115. (Pubitemid 30036343)
117. Mukai H, Katsumata N, Ando M, Watanabe T. (2010). Safety and efcacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer. Am J Clin Oncol 33:32-35.
118. Mukhopadhyay P, Rajesh M, Pan H, Patel V, Mukhopadhyay B, Bátkai S, Gao B, Haskó G, Pacher P. (2010). Cannabinoid-2 receptor limits infammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med 48:457-467.
119. Nakayama T, Sato W, Yoshimura A, Zhang L, Kosugi T, Campbell-Tompson M, Kojima H, Croker BP, Nakagawa T. (2010). Endothelial von Willebrand factor release due to eNOS defciency predisposes to thrombotic microangiopathy in mouse aging kidney. Am J Pathol 176:2198-2208.
120. Nangaku M. (2004). Hypoxia and tubulointerstitial injury: a fnal common pathway to end-stage renal failure. Nephron Exp Nephrol 98:e8-12.
121. Nazneen A, Razzaque MS, Liu D, Taguchi T. (2002). Possible role of Ets-1 and MMP-1 in matrix remodeling in experimental cisplatin nephropathy. Med Electron Microsc 35:242-247. (Pubitemid 36205684)
122. Nezhat F, Wadler S, Muggia F, Mandeli J, Goldberg G, Rahaman J, Runowicz C, Murgo AJ, Gardner GJ. (2004). Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecol Oncol 93:144-148. (Pubitemid 38429563)
123. Nielsen D, Dombernowsky P, Larsen SK, Hansen OP, Skovsgaard T. (2000). Epirubicin or epirubicin and cisplatin as frst-line therapy in advanced breast cancer. A phase III study. Cancer Chemother Pharmacol 46:459-466.
124. Nonclercq D, Toubeau G, Laurent G, Tulkens PM, Heuson-Stiennon JA. (1989). Tissue injury and repair in the rat kidney after exposure to cisplatin or carboplatin. Exp Mol Pathol 51:123-140. (Pubitemid 20001027)
125. Noris M, Remuzzi G. (2008). Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clin Exp Immunol 151:199-209.
126. Owens DM, Keyse SM. (2007). Diferential regulation of MAP kinase signalling by dual-specifcity protein phosphatases. Oncogene 26:3203-3213. (Pubitemid 46763015)
127. Pabla N, Dong Z. (2008). Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994-1007. (Pubitemid 351543900)
128. Pabla N, Murphy RF, Liu K, Dong Z. (2009). Te copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 296:F505-F511.
129. Park TK, Kim SN, Kim SW, Kim GE, Suh CO. (2000). Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors. J Korean Med Sci 15:436-441.
130. Peyrou M, Hanna PE, Cribb AE. (2007). Cisplatin, gentamicin, and p-aminophenol induce markers of endoplasmic reticulum stress in the rat kidneys. Toxicol Sci 99:346-353. (Pubitemid 47250391)
131. Ramesh G, Reeves WB. (2002). TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835-842.
132. Ramesh G, Reeves WB. (2003). TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285:F610-F618. (Pubitemid 37140245)
133. Ramesh G, Reeves WB. (2004). Infammatory cytokines in acute renal failure. Kidney Int Suppl: S56-S61. (Pubitemid 39281716)
134. Ramesh G, Reeves WB. (2005). p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 289:F166-F174. (Pubitemid 40863584)
135. Ramesh G, Kimball SR, Jeferson LS, Reeves WB. (2007). Endotoxin and cisplatin synergistically stimulate TNF-alpha production by renal epithelial cells. Am J Physiol Renal Physiol 292: F812-F819. (Pubitemid 46220550)
136. Razzaque MS, Koji T, Kumatori A, Taguchi T. (1999). Cisplatin-induced apoptosis in human proximal tubular epithelial cells is associated with the activation of the Fas/Fas ligand system. Histochem Cell Biol 111:359-365. (Pubitemid 29274005)
137. Razzaque MS, Harada T, Taguchi T. (1996). Signifcance of increased accumulation of type VI collagen and transforming growth factor beta 1 in tubulointerstitial damage in hypertensive nephrosclerosis: an immunohistochemical study. J Int Med Res 24:199-208. (Pubitemid 26120049)
138. Retz M, Lehmann J, Trocha C, Loch T, Seppelt U, Fischer C, Pinkenburg FA, Timm KJ, Wellek S, Stöckle M. (2000). Long term follow-up of combined radiochemotherapy for locally advanced bladder carcinoma. Cancer 89:1089-1094.
139. Rinaldi M, Crinò L, Scagliotti GV, Mosconi AM, De Marinis F, Gridelli C, Selvaggi G, Della Giulia M, Darwish S, Porrozzi S, Novello S, Cipri A, Bartolucci R, Calandri C, Tonato M. (2000). A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two diferent cisplatin dose levels: a phase II randomized trial. Ann Oncol 11:1295-1300.
140. Rodriguez-Barbero A, L'Azou B, Cambar J, López-Novoa JM. (2000). Potential use of isolated glomeruli and cultured mesangial cells as in vitro models to assess nephrotoxicity. Cell Biol Toxicol 16:145-153.
141. Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G. (2002). Phase III randomised trial comparing paclitaxel/ carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 13:1539-1549. (Pubitemid 35331451)
142. Royer B, Guardiola E, Polycarpe E, Hoizey G, Delroeux D, Combe M, Chaigneau L, Samain E, Chaufert B, Heyd B, Kantelip J P, Pivot X. (2005). Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: infuence of protein binding. Anticancer Drugs 16:1009-1016. (Pubitemid 41416092)
143. Saad SY, Arafah MM, Najjar TA. (2007). Efects of mycophenolate mofetil on cisplatin-induced renal dysfunction in rats. Cancer Chemother Pharmacol 59:455-460. (Pubitemid 46122323)
144. Saad AA, Youssef MI, El-Shennawy LK. (2009). Cisplatin induced damage in kidney genomic DNA and nephrotoxicity in male rats: the protective efect of grape seed proanthocyanidin extract. Food Chem Toxicol 47:1499-1506.
145. Safrstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J. (1986). Cisplatin nephrotoxicity. Am J Kidney Dis 8: 356-367. (Pubitemid 17235083)
146. Saleh S, El-Demerdash E. (2005). Protective efects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic Clin Pharmacol Toxicol 97:91-97. (Pubitemid 41021108)
147. Santos NA, Bezerra CS, Martins NM, Curti C, Bianchi ML, Santos AC. (2008). Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol 61:145-155. (Pubitemid 47512636)
148. Sárosi V, Lénárt T. (2003). Gemcitabine-cisplatin combination in the frst line treatment of non-small cell lung cancer. Our experience and analysis of safety. Magy Onkol 47:189-193.
149. Sastry J, Kellie SJ. (2005). Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 22:441-445. (Pubitemid 40993608)
150. Schäfer A, Bauersachs J. (2008). Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol 6:52-60.
151. Schnermann J, Levine DZ. (2003). Paracrine factors in tubuloglomerular feedback: adenosine, ATP, and nitric oxide. Annu Rev Physiol 65:501-529. (Pubitemid 38249165)
152. Schrier RW, Chen YC, Cadnapaphornchai MA. (2004). From fnch to fsh to man: role of aquaporins in body fuid and brain water regulation. Neuroscience 129:897-904. (Pubitemid 39556242)
153. Sculier JP, Laftte JJ, Efremidis A, Florin MC, Lecomte J, Berchier MC, Richez M, Berghmans T, Scherpereel A, Meert AP, Koumakis G, Leclercq N, Paesmans M, Van Houtte P; European Lung Cancer Working Party (ELCWP). (2008). A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer. Ann Oncol 19:1691-1697.
154. Sekine I, Sumi M, Ito Y, Kato T, Fujisaka Y, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T. (2007). Phase I study of cisplatin analogue nedaplatin, paclitaxel, and thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Jpn J Clin Oncol 37:175-180. (Pubitemid 47090691)
155. Seth R, Yang C, Kaushal V, Shah SV, Kaushal GP. (2005). p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J Biol Chem 280:31230-31239. (Pubitemid 41291860)
156. Shamseddine AI, Otrock ZK, Khalifeh MJ, Yassine HR, Charafeddine M, Abdel-Khalek Z, Chehal A, Bitar N, Jalloul R, Dheiny M, Dandashi A, Wehbeh M, El-Saghir NS. (2006). A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as frst-line treatment in metastatic breast cancer. Oncology 70:330-338. (Pubitemid 46074942)
157. Shord SS, Tompson DM, Krempl GA, Hanigan MH. (2006). Efect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. Anticancer Drugs 17:207-215.
158. Siddik ZH. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279.
159. Skálová S. (2005). Te diagnostic role of urinary N-acetyl-beta-D-glucosaminidase (NAG) activity in the detection of renal tubular impairment. Acta Medica (Hradec Kralove) 48:75-80.
160. Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD. (2009). Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer 45:3213-3219.
161. Sung MJ, Kim DH, Jung YJ, Kang KP, Lee AS, Lee S, Kim W, Davaatseren M, Hwang JT, Kim HJ, Kim MS, Kwon DY, Park SK. (2008). Genistein protects the kidney from cisplatin-induced injury. Kidney Int 74:1538-1547.
162. Taguchi T, Nazneen A, Abid MR, Razzaque MS. (2005). Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol 148:107-121. (Pubitemid 43264925)
163. Tamada S, Asai T, Kuwabara N, Iwai T, Uchida J, Teramoto K, Kaneda N, Yukimura T, Komiya T, Nakatani T, Miura K. (2006). Molecular mechanisms and therapeutic strategies of chronic renal injury: the role of nuclear factor kappaB activation in the development of renal fbrosis. J Pharmacol Sci 100:17-21. (Pubitemid 43161609)
164. Tanaka T, Kojima I, Ohse T, Inagi R, Miyata T, Ingelfnger JR, Fujita T, Nangaku M. (2005). Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity. Am J Physiol Renal Physiol 289:F1123-F1133. (Pubitemid 41447069)
165. Tadhani R, Pascual M, Bonventre JV. (1996). Acute renal failure. N Engl J Med 334:1448-1460. (Pubitemid 126590563)
166. Tiseo, M., Boni, L., and Ardizzoni, A.(2006). Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a diference? J Clin Oncol 23:6276-6277; author reply 6277-6278.
167. Togna GI, Togna AR, Franconi M, Caprino L. (2000). Cisplatin triggers platelet activation. Tromb Res 99:503-509.
168. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. (2003). Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14:1-10. (Pubitemid 36026291)
169. Tsang RY, Al-Fayea T, Au HJ. (2009). Cisplatin overdose: toxicities and management. Drug Saf 32:1109-1122.
170. Tsuji T, Kato A, Yasuda H, Miyaji T, Luo J, Sakao Y, Ito H, Fujigaki Y, Hishida A. (2009). Te dimethylthiourea-induced attenuation of cisplatin nephrotoxicity is associated with the augmented induction of heat shock proteins. Toxicol Appl Pharmacol 234:202-208.
171. Tsuruya K, Tokumoto M, Ninomiya T, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Hirakata H, Iida M. (2003). Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways. Am J Physiol Renal Physiol 285:F208-F218. (Pubitemid 36871193)
172. Uehara T, Watanabe H, Itoh F, Inoue S, Koshida H, Nakamura M, Yamate J, Maruyama T. (2005). Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol 79:451-460. (Pubitemid 41191383)
173. Vasey PA, Paul J, Birt A, Junor EJ, Reed NS, Symonds RP, Atkinson R, Graham J, Crawford SM, Coleman R, Tomas H, Davis J, Eggleton SP, Kaye SB. (1999). Docetaxel and cisplatin in combination as frst-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol 17:2069-2080. (Pubitemid 29318837)
174. Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. (2008). Cardiovascular risk in long-term survivors of testicular cancer. Cancer 112:1949-1953. (Pubitemid 351574070)
175. Vickers AE, Rose K, Fisher R, Saulnier M, Sahota P, Bentley P. (2004). Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol 32:577-590. (Pubitemid 39258463)
176. Victor VM, Rocha M, Solá E, Bañuls C, Garcia-Malpartida K, Hernández-Mijares A. (2009). Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 15:2988-3002.
177. Wainford RD, Weaver RJ, Stewart KN, Brown P, Hawksworth GM. (2008). Cisplatin nephrotoxicity is mediated by gamma glutam-yltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology 249:184-193.
178. Wang D, Lippard SJ. (2005). Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320. (Pubitemid 41130944)
179. Wei Q, Dong G, Yang T, Megyesi J, Price PM, Dong Z. (2007a). Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 293:F1282-F1291. (Pubitemid 47583963)
180. Wei Q, Dong G, Franklin J, Dong Z. (2007b). Te pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 72:53-62. (Pubitemid 47014446)
181. Winston JA, Safrstein R. (1985). Reduced renal blood fow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 249:F490-F496. (Pubitemid 16185880)
182. Yamate J, Sato K, Ide M, Nakanishi M, Kuwamura M, Sakuma S, Nakatsuji S. (2002). Participation of diferent macrophage populations and myofbroblastic cells in chronically developed renal interstitial fbrosis after cisplatin-induced renal injury in rats. Vet Pathol 39:322-333.
183. Yamate J, Machida Y, Ide M, Kuwamura M, Kotani T, Sawamoto O, LaMarre J. (2005). Cisplatin-induced renal interstitial fbrosis in neonatal rats, developing as solitary nephron unit lesions. Toxicol Pathol 33:207-217. (Pubitemid 40381448)
184. Yang T, Vesey DA, Johnson DW, Wei MQ, Gobe GC. (2007). Apoptosis of tubulointerstitial chronic infammatory cells in progressive renal fbrosis after cancer therapies. Transl Res 150:40-50. (Pubitemid 46950943)
185. Yao X, Panichpisal K, Kurtzman N, Nugent K. (2007). Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115-124. (Pubitemid 47262919)
186. Yatsu T, Aoki M, Inagaki O. (2003). Preventive efect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in rats. Eur J Pharmacol 461:191-195. (Pubitemid 36174037)
187. Yokoo K, Murakami R, Matsuzaki T, Yoshitome K, Hamada A, Saito H. (2009). Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin Exp Nephrol 13:578-584.
188. Yoshiki N, Kubota T, Aso T. (2000). Expression and localization of inducible nitric oxide synthase in human non-pregnant and early pregnant endometrium. Mol Hum Reprod 6:283-287. (Pubitemid 30120624)
189. Zhang L, Hanigan MH. (2003). Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin. J Pharmacol Exp Ter 306: 988-994. (Pubitemid 37025305)
190. Zhang B, Ramesh G, Norbury CC, Reeves WB. (2007). Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 72:37-44. (Pubitemid 47014442)
191. Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB. (2008). TLR4 signaling mediates infammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 19:923-932.
192. Zhou H, Kato A, Yasuda H, Miyaji T, Fujigaki Y, Yamamoto T, Yonemura K, Hishida A. (2004). Te induction of cell cycle regulatory and DNA repair proteins in cisplatin-induced acute renal failure. Toxicol Appl Pharmacol 200:111-120. (Pubitemid 39346018)